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Abstract
Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization
treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility
treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol,
GnRH agonist (GnRHa) triggering of ovulation, blastocyst transfer and embryo/oocyte vitrification, renders feasible
the elimination of OHSS in connection with ovarian hyperstimulation for IVF treatment. The proposed current
algorithm is based on the number of follicles developed after ovarian stimulation, setting a cut-off level at the
development of 18 or more follicles. Further, fulfilling this criterion, the algorithm is based on four decision-making
points: the final day of patient work-up, the day of triggering final oocyte maturation, day-1 post oocyte pick-up
(OPU) and day-5 post OPU.
If the physician decides to administer hCG for final oocyte maturation regardless the type of analogue used, he has
the option on day-1 to either freeze all embryos or to proceed to day-5. On this day, based on the clinical
condition of the patient, a decision should be made to either transfer a single blastocyst or to vitrify all blastocysts
available. However, this strategy will not guarantee an OHSS free luteal phase especially if a pregnancy occurs. If
the physician decides to trigger ovulation with GnRHa, feasible only with the antagonist protocol, embryos can be
cultured until day-5. On this day a transfer can be performed with no risk of OHSS and spare blastocysts may be
vitrified. Alternatively, on day-1 or day-2 post OPU, all embryos could be frozen.
Hopefully, in a near future, GnRHa triggering and vitrification of oocytes will become everyday practice. Only the
combined use of a GnRH antagonist protocol with GnRHa triggering and subsequent single blastocyst transfer or
embryo/oocyte freezing will completely abolish the risk of OHSS after ovarian hyperstimulation.
Background
The most feared complication of IVF-related ovarian sti-
mulation for the patient as well as the doctor is the
development of ovarian hyperstimulation syndrome
(OHSS) [1]; a syndrome, which in its severe form leads
to hospitalization and in the worst case scenario fatal
complications. The incidence of clinically significant
OHSS is 2-3%, however, milder forms of OHSS might
develop in up to 20-30% of all IVF patients [2].
The basis for OHSS development is the development
of multiple follicles. Once this criterion is fulfilled, the
second factor needed for the development of the severe
form of the disease is either the exogenous administra-
tion of HCG for final oocyte maturation - as is the cur-
rent practice - or the establishment of a pregnancy and
the production of endogenous HCG from the implant-
ing embryo [3]. Therefore, two types of OHSS have
been identified: the early onset OHSS which is self-lim-
ited in case no pregnancy occurs, and the late onset
OHSS which develops ten days or more after the egg
retrieval [4]. In contrast to the early OHSS the late
onset OHSS is poorly correlated to the ovarian response
after stimulation.
All late onset OHSS cases are related to pregnancy
and these cases often require hospitalization. Unfortu-
nately these late OHSS cases render the prediction of
OHSS a difficult task [5] and the methods used to pre-
dict the condition prior to stimulation have been shown
having limited success [6].
The protocol of choice for potential high-responder
patients prone to develop OHSS should be the GnRH
antagonist protocol, as it has been shown to decrease
the incidence of OHSS significantly [7,8]. Furthermore,
it allows the utilization of a GnRHa to induce final
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T h ep o o l e de v i d e n c es h o w st h a tb yt r i g g e r i n gw i t h
GnRHa in patients co-treated with a GnRH antagonist
protocol, not only is OHSS minimized, but also this
concept allows embryo transfer in the hyper-responding
patient with a reproductive outcome comparable to that
seen after hCG triggering as long as adequate luteal sup-
port can be achieved [9].
At the same time, the development of the vitrification
procedure has improved the embryo survival rate as
compared to the classical method of slow freezing [10].
Thus, considering the different modalities that the phy-
sician has available, we below propose an algorithm for
OHSS high-risk patients. The algorithm may easily be
applied according to the preferences of the doctor and
his patient and refers to both GnRH-analogues, GnRH
agonist as well as GnRH antagonist.
Algorithm
The algorithm is based on two decision making time
periods: the follicular phase and the luteal phase; and
four time-points: the final day of patient work-up, the
day of ovulation triggering, day-1 post-OPU and day-5
post-OPU (Figure 1). However, the OHSS reducing
strategy obviously already starts when the physician
evaluates the patient’s ovarian reserve and thus the risk
for hyperstimulation prior to stimulation [6].
Final day of patient work-up (Decision point 1)
A mandatory step in the ovarian stimulation for IVF is
firstly the gonadotropin dose and secondly the protocol.
Regarding the prediction of hyper-response, recent evi-
dence suggests the superiority of AMH over antral folli-
cle count [11,12]. In a prospective cohort of 262 IVF
cycles with 8% moderate and severe OHSS, Lee et al
showed that an AMH cut-off value of 3.36 ng/mL gave
a sensitivity of 90.5% and a specificity of 81.3% to pre-
dict OHSS [11,12]. Regarding the antral follicle count,
Kwee et al have shown that a cut off level of > 14 antral
follicles gave the highest sensitivity (82%) and specificity
(89%) and also the highest accuracy. With a prevalence
of 15% for high response (defined as > 20 oocytes in an
D-0 D-HCG OPU+1 OPU+5
Figure 1 New proposed algorithm for OHSS prevention and treatment. The upper pathway (traditional) applies to both the GnRH agonist
and GnRH antagonist protocol. The lower pathway (innovative) applies only to the GnRH antagonist protocol.
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these thresholds, a woman considered to be at high risk
of developing OHSS should be stimulated with low
doses of gonadotropins and preferably co-treated with a
GnRH antagonist. Nevertheless, individualization of
doses and protocol utilized depends on the clinical
experience of the treating physician.
Although we use certain cut-off values and our clini-
cal experience to avoid hyperstimulation, we many
times fail and the patients ends-up with an excessive
ovarian response. As mentioned, Papanikolaou and col-
leagues have shown that the first prerequisite for
OHSS development is the development of multiple fol-
licles and specifically more than 18 follicles with a dia-
meter above 11 mm and/or above 5000 pg/ml
Estradiol [2,14]. Thus, from the late follicular phase
and onwards, it becomes clear which patient is poten-
tially at high-risk of developing OHSS. Therefore, a
modification of the ovarian stimulation should be
applied, either decreasing the dose of gonadotropins or
administering the triggering bolus of hCG earlier
(when three follicles reach the size of 17 mm). In
GnRH antagonist protocols, this has been shown to be
more efficient compared to later administration at a
larger follicular size [15,16]. Both these actions intend
to induce the regression of small and medium sized
follicles initially recruited, which will decrease the risk
of OHSS.
Day of Triggering final oocyte maturation (Decision 2)
Once the patient has met the criterion set above, the
clinician has two options for triggering ovulation: either
to administer a lower dose of HCG (250 mcg rec-HCG
or 3,300 to 5000 IU urinary hCG), which is the tradi-
tional way, applicable in GnRH agonist as well as GnRH
antagonist protocols [16]; or to administer GnRHa for
final oocyte maturation (0.2 mg Triptorelin or 0.5 mg
Buserelin or 1 mg Leuprolide), the innovative way,
applicable only in the Antagonist protocol [17].
(i) Traditional way with HCG-triggering
hCG for triggering of final oocyte maturation has been
the gold standard treatment for decades, clinically
approved and highly efficient. This triggering concept is
the only one to be applied in patients co-treated with a
long GnRH agonist protocol. However, OHSS may still
occur despite administration of lower doses of hCG
instead of the standard 10,000 IU dose [18]. Specifically
in high-risk patients the OHSS incidence might reach
up to 30% in case of embryo transfer and the achieve-
ment of a pregnancy [19]. On the other hand the pre-
sence of exogenous HCG for 8 days in circulation
during the luteal phase [18] secures the appropriate
function of the corpora lutea and hence the implanta-
tion of the transferred embryo.
(ii) Innovative way with GnRH Agonist triggering
the newer option, using GnRHa triggering, minimizes
the risk of OHSS and secures the appropriate matura-
tion of oocytes. The oocyte pick-up after GnRHa trig-
gering should be performed within 34-35 hours.
H o w e v e r ,G n R H at r i g g e r i n gi sp o s s i b l eo n l yw h e nu s i n g
a GnRH antagonist protocol and requires modified
luteal support in order to be as efficient as hCG trigger-
ing [19-21]. The complete eradication of OHSS has
made the GnRHa triggering concept the protocol of
choice in oocyte donation cycles [22]. In parallel, in IVF
with fresh embryo transfer, a new meta-analysis indi-
cates that if luteal support is modified with either a
bolus of hCG on the day of OPU, alternate doses of rec-
LH, or intense luteal support with intramuscular proges-
terone and estradiol patches, the delivery rate is com-
parable to that seen after hCG triggering [9].
Day-1 in luteal phase post-OPU (Decision 3)
O nt h ef i r s td a ya f t e rt h eo o cyte retrieval, a decision
should be made whether to proceed with luteal phase
support and subsequently embryo transfer or to freeze
all embryos. On this day, the physician will have per-
formed an ultrasound measuring the quantity of fluid in
the pouch of Douglas and the ovarian volume; he should
also assess the physical condition of the patient i.e. the
degree of pain, discomfort, use of painkillers, and
breathing difficulty [15]. In addition, the number of fer-
tilized oocytes will be known. Taking these facts into
account and adding the efficacy of the cryopreservation
program of the unit, a decision can be made whether to
proceed with the embryo transfer or to freeze all
embryos.
(i) Traditional way after HCG-triggering
If the patient on the planned day of triggering already
h a sd e v e l o p e ds i g n so rs y m p t o m so fe a r l yO H S Si ti s
advisable to freeze all embryos at the 2PN stage or at
the cleavage stage (day-2/3) and to cancel the embryo
transfer. With appropriate counseling the patient will
not regard a total freeze as a failure, but rather as a pre-
ventive measure, ensuring her health. Importantly, with
a good cryo-program her chances of obtaining a preg-
nancy will not be reduced [23]. Alternatively, given that
the patient can tolerate a milder hyperstimulation, a
blastocyst transfer can be planned, if her condition does
not worsen during the observational period. Neverthe-
less, the risk of late onset OHSS cannot be excluded
with this approach.
(ii) Innovative way after GnRH Agonist triggering
As mentioned above, in the new studies focusing on
intense luteal support [19] or supplementation with
LH-activity [20,21,24] pregnancy rates are comparable
to the standard HCG triggering protocol and at the
same time OHSS is eliminated. Therefore, a fresh
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might be a more preferred strategy instead of a total
freeze. Nevertheless, for those yet not convinced about
the reproductive outcome after GnRH agonist trigger-
ing followed by modified luteal phase support, a total
freeze is still an option.
Day-5 in luteal phase post-OPU (Decision 4)
Prior to a day-5 transfer, an ultrasound should be per-
formed in combination with blood tests (Hematocrit,
WBC, PLT, PT, aPTT, Fibrinogen, D-Dimers, Urea,
Creatinine, ALT, AST, gGT, ALP, K, Na, Total Protein,
Albumin) to identify patients at high risk of developing
severe late onset OHSS. If the evaluation is reassuring a
single blastocyst transfer can be performed, followed by
vitrification of spare blastocysts [25]. If a patient is con-
sidered at high risk of developing OHSS - as might
o f t e nb et h ec a s ei fh C Gt r i g g e r i n gh a sb e e nu t i l i z e d-
the embryo transfer should be cancelled. For units
working with slow freezing only or having low blastocyst
development rates, an alternative option is to freeze half
of the embryos at the cleavage stage and allow the rest
to develop into blastocysts. If the condition of the
patient permits it, a blastocyst transfer is performed and
surplus embryos are cryopreserved.
(i) Traditional way after hCG-triggering
on day-5 if the patient confirms her good physical con-
dition and blood tests and/or ultrasound examination
are reassuring, a single blastocyst transfer should be per-
formed. Possible supernumerary blastocysts should be
vitrified. Importantly, the patient has to be informed
that the risk of late OHSS still exists. In contrast, if the
patient has developed signs of early onset OHSS, all
blastocysts should be cryopreserved.
(ii) Innovative way after GnRH Agonist triggering
usually no signs of early OHSS will be present and
hence the transfer of a single or even two blastocysts in
older patients will not increase the risk of late onset
OHSS [9]. Supernumerary blastocysts can be vitrified
for future use.
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